Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study

Starting soon · Not applicable

Conditions studied: Locally Advanced Non-small Cell Lung Cancer (NSCLC)

In brief

The PREHAB study focuses on patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemotherapy and/or immunotherapy prior to surgical resection. These systemic treatments frequently impair patients' physiological reserve, reduce physical fitness, and may occasionally lead to cancellation of surgery. Surgery itself carries a substantial risk of cardiorespiratory complications and long-term functional decline. The primary objective of this study is to determine whether a supervised exercise program, initiated concomitantly with systemic therapy and continued until surgery, can improve cardiorespiratory fitness, surgical tolerance, and postoperative outcomes. A total of 74 patients will be randomly assigned to one of two groups: an "intervention" group participating in three weekly sessions of supervised endurance and resistance training for 12 to 16 weeks under the guidance of a physiotherapist, and a "control" group receiving usual care without a structured exercise program. The primary endpoint will be peak oxygen uptake (VO₂peak). Secondary outcomes will include postoperative complication rates, length of hospital stay, pulmonary function, skeletal muscle mass, and quality of life. Intervention-related risks, primarily falls or overexertion, will be mitigated through professional supervision. This multicenter study, with recruitment scheduled to begin in 2026, is expected to provide robust evidence regarding the effectiveness of targeted exercise training in improving preoperative fitness and postoperative recovery in patients with locally advanced NSCLC.

Key facts

Study ID

NCT07479407

Run by

Hôpital du Valais

People needed

74

Starts

2026-04-01

Expected to finish

2029-04-01

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years.
• Confirmed diagnosis of stage IIB, IIIA, IIIB or oligo-metastatic stage IV NSCLC.
• Planned induction therapy with either chemotherapy, immunotherapy or a combination of immuno-chemotherapy followed by an anatomical pulmonary resection.
• Absence of musculoskeletal conditions preventing safe physical exercise.
• Absence of any history of uncontrolled or unstable cardiac disease.
• Agreement to participate in the study by signing the study specific informed consent form.

You may not qualify if…

• Pregnancy (confirmed by a test if applicable).
• Induction therapy already initiated.
• Inability to walk independently.
• Lack of decision-making capacity.
• Oxygen-dependency before the initiation of the induction protocol.
• No capacity for discernment.
• Does not speak French.

Where it is running

• Hôpitaux Universitaires de Genève — Geneva, Canton of Geneva, Switzerland
• Centre Hospitalier Universitaire Vaudois — Lausanne, Canton of Vaud, Switzerland
• Hôpital de Sion — Sion, Valais, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.